# A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

> **NCT00089492** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 64 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Optimized Background ARVs
- **DRUG:** enfuvirtide [Fuzeon]
- **DRUG:** enfuvirtide [Fuzeon]

## Key facts

- **NCT ID:** NCT00089492
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2016-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089492, "A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00089492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*